Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCI Services Inc.

Division of Cardinal Health Inc.

Latest From PCI Services Inc.

BIO Notebook Day 4: Gottlieb Seeks Early Engagement On Gene Therapy; Ireland’s Brexit Opportunities; AMAG’s Bremelanotide Strategy; Alzheimer’s ‘Learnings’

US FDA to head off cell/gene therapy manufacturing issues with pre-IND meetings; Republic of Ireland will “chase any opportunities” for business partners stemming from Brexit, even while hoping UK reconsiders EU departure; AMAG won’t follow the flibanserin PR approach with newly submitted female sexual dysfunction drug bremelanotide; United Neuroscience CMO Ajay Verma says Alzheimer’s trial setbacks are “learnings,” with progress toward novel therapies moving faster than it has for cancer and HIV.

Regenerative Medicine Neurology

BIO Notebook Day 4: Gottlieb Seeks Early Engagement On Gene Therapy; Ireland’s Brexit Opportunities; AMAG’s Bremelanotide Strategy; Alzheimer’s ‘Learnings’

US FDA to head off cell/gene therapy manufacturing issues with pre-IND meetings; Republic of Ireland will “chase any opportunities” for business partners stemming from Brexit, even while hoping UK reconsiders EU departure; AMAG won’t follow the flibanserin PR approach with newly submitted female sexual dysfunction drug bremelanotide; United Neuroscience CMO Ajay Verma says Alzheimer’s trial setbacks are “learnings,” with progress toward novel therapies moving faster than it has for cancer and HIV.

Regenerative Medicine Neurology

2018 Preparation: PD-1 Predictions And Commercialization Challenges

What's next for the PD-1 market, a cancer therapy area that exploded in 2017 as recently launched products secured ever more approvals? Maria Whitman, managing principal at sales and marketing firm ZS Associates, talks about challenges facing the booming immuno-oncology market and shares her predictions for 2018.

ImmunoOncology Business Strategies

Pipeline Watch: Patisiran, Etrolizumab, ALKS8700 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cardinal Health Inc.
  • Senior Management
  • Richard S Sauter, CEO
    Michael F Sandler, VP, CFO
    Daniel F Gerner, Pres. & COO
  • Contact Info
  • PCI Services Inc.
    Phone: (609) 665-9399
    K Street & Erie Avenue
    Philadelphia, PA 19124
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register